Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




miRNAs Show Promise for Treatment of Ovarian Cancer

By LabMedica International staff writers
Posted on 21 Aug 2012
Results of a recent study suggest that microRNAs (miRNAs) have excellent therapeutic potential, which justifies continued research efforts designed to turn them into usable anticancer agents.

Investigators at the Georgia Institute of Technology (Atlanta, GA, USA) worked with two well-defined mRNA species, MiR-7 and MiR-128. More...
They conducted a series of controlled experiments in which these two miRNAs--previously implicated in ovarian cancer onset/progression--were individually transfected into a well-defined ovarian cancer (HEY) cell line, and the consequence on global patterns of gene expression was monitored using microarray technology.

The results published in the August 1, 2012, online edition of the journal BMC Medical Genomics revealed that the changes in gene expression induced by the individual miRNAs were functionally coordinated but distinct between the two miRNAs. MiR-7 transfection into ovarian cancer cells induced changes in cell adhesion and other developmental networks previously associated with epithelial-mesenchymal transitions (EMT) and other processes linked with metastasis. In contrast, miR-128 transfection induced changes in cell cycle control and other processes commonly linked with cellular replication.

“Each inserted miRNA created hundreds of thousands of gene expression changes, but only about 20% of them were caused by direct interactions with mRNAs,” said senior author Dr. John McDonald, professor of biology at the Georgia Institute of Technology. “The majority of the changes were indirect – they occurred downstream and were consequences of the initial reactions. miRNAs have evolved for millions of years in order to coordinately regulate hundreds to thousands of genes together on the cellular level. If we can understand which miRNAs affect which suites of genes and their coordinated functions, it could allow clinicians to attack cancer cells on a systems level, rather than going after genes individually”.

Related Links:
Georgia Institute of Technology




Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
Thyroid Test
Anti-Thyroid EIA Test
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Characterization of EV separated by distinct methods (Photo courtesy of Yuanyuan Liu, Yanbin Guo et al. Engineering, doi.org/10.1016/j.eng.2025.12.009)

Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis

Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read more

Molecular Diagnostics

view channel
Image: Associate Professor Arutha Kulasinghe and non-small cell lung cancer cell (Photo courtesy of The University of Queensland)

Blood-Based Proteomic Test May Predict Treatment Response in Non-Small Cell Lung Cancer

Lung cancer remains the leading cause of cancer death, with non-small cell lung cancer (NSCLC) accounting for most cases. Treatment decisions are often made without a clear indication of how a patient... Read more

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.